You are here

Article Text

Article menu
Download PDFPDF
Letter
Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis
  1. A Spadaro,
  2. F Ceccarelli,
  3. R Scrivo,
  4. G Valesini
  1. Dipartimento di Clinica e Terapia Medica, Rheumatology Unit, Università di Roma, Rome, Italy
  1. Professor Antonio Spadaro, Dipartimento di Clinica e Terapia Medica, Rheumatology Unit, Sapienza, Università di Roma, Azienda Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy; a.spadaro.reuma{at}virgilio.it

http://dx.doi.org/10.1136/ard.2007.085951

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The recent analysis of data included in the Stockholm TNFα Follow- Up (STURE) registry showed that the concomitant use of methotrexate (MTX) with etanercept (ETN), adalimumab or infliximab was associated with long-term drug survival of anti-tumour necrosis factor (TNF) agents in patients with psoriatic arthritis (PsA).1 The positive effect of MTX was primarily linked to fewer drop-outs due to adverse events.1 This analysis did not consider each anti-TNF drug subgroup. For this reason we determined the cumulative probability of taking ETN with or without MTX in a large cohort of patients.

    We prospectively studied 82 patients, admitted to our rheumatological unit since 2001, affected by PsA, classified …

    View Full Text

    Footnotes

    • Competing interests: None declared.

    • Ethics approval: Ethics approval was obtained.